青霉素过敏对革兰阴性血流感染经验性碳青霉烯使用的影响:抗菌药物管理机遇
这项回顾性匹配队列研究在两家社区医院开展,评估青霉素过敏与社区起病革兰阴性血流感染经验性碳青霉烯使用的关系,以及抗菌药物管理干预的效果。结果显示青霉素过敏患者经验性碳青霉烯使用率更高(27% vs 12%,p=0.002),青霉素过敏(OR 3.98,95%CI 1.98-8.45)和既往β-内酰胺使用(OR 2.72,95%CI 1.07-6.64)是独立相关因素,而管理干预与碳青霉烯使用下降相关(OR 0.41,95%CI 0.16-0.94);青霉素过敏患者中干预后碳青霉烯降阶梯中位时间显著缩短(2.0 vs 4.2天,p=0.004)。
要点
- 青霉素过敏使社区起病革兰阴性血流感染经验性碳青霉烯使用风险增加近4倍。
- 抗菌药物管理干预可降低碳青霉烯总体使用并缩短青霉素过敏患者降阶梯时间。
- 既往β-内酰胺使用也是经验性碳青霉烯使用的独立相关因素。
核心结论
- 青霉素过敏是社区起病革兰阴性血流感染经验性碳青霉烯使用的重要促进因素。
- 抗菌药物管理干预可改变这一现象,成功降低总体碳青霉烯使用及青霉素过敏患者的碳青霉烯疗程。
研究设计与样本
- 回顾性匹配队列研究,纳入2010年1月1日至2015年6月30日两家大型社区医院住院的社区起病革兰阴性血流感染成人患者。
- 针对青霉素过敏和碳青霉烯使用的抗菌药物管理干预于2014年1月1日全面实施。
- 采用多因素logistic回归分析青霉素过敏和管理干预对经验性碳青霉烯使用的影响,Kaplan-Meier分析评估干预前后青霉素过敏患者碳青霉烯降阶梯时间。
主要发现
- 青霉素过敏患者(n=140)经验性碳青霉烯使用率为27%,无青霉素过敏者(n=140)为12%(p=0.002)。
- 多因素校正后,青霉素过敏(OR 3.98,95%CI 1.98-8.45)和既往β-内酰胺使用(OR 2.72,95%CI 1.07-6.64)与经验性碳青霉烯使用独立相关。
- 抗菌药物管理干预与碳青霉烯使用下降相关(OR 0.41,95%CI 0.16-0.94)。
- 青霉素过敏且接受经验性碳青霉烯的患者中,干预后碳青霉烯降阶梯中位时间显著短于干预前(2.0 vs 4.2天,p=0.004)。
临床怎么用
- 临床应关注青霉素过敏标签对经验性碳青霉烯选择的驱动作用,避免不必要的广谱使用。
- 抗菌药物管理项目可针对青霉素过敏评估和碳青霉烯使用进行干预,以促进降阶梯和缩短疗程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Retrospective matched-cohort study evaluating association between penicillin allergy and empirical carbapenem use in gram-negative bloodstream infections (BSIs) and utility of antimicrobial stewardship interventions in reducing carbapenem utilization. METHODS: Hospitalized adults with community-onset gram-negative BSI from January 1, 2010, to June 30, 2015, at two large community hospitals in Columbia, SC, were identified. Antimicrobial stewardship interventions targeting penicillin allergy and carbapenem utilization were fully implemented January 1, 2014. Multivariate logistic regression was used to examine impact of penicillin allergy and antimicrobial stewardship interventions on empirical carbapenem use. Kaplan-Meier analysis was used to evaluate time to carbapenem deescalation in patients with penicillin allergy before and after interventions. RESULTS: Patients with penicillin allergy (n=140) were more likely to receive empirical carbapenem therapy for community-onset gram-negative BSI compared to those without penicillin allergy (n=140) (27% vs 12%, p=0.002). After adjustments in the multivariate model, penicillin allergy (odds ratio [OR] 3.98, 95% confidence interval [CI] 1.98-8.45) and prior β-lactam use (OR 2.72, 95% CI 1.07-6.64) were independently associated with empirical carbapenem use, whereas antimicrobial stewardship interventions were associated with decline in carbapenem utilization (OR 0.41, 95% CI 0.16-0.94). Among patients with penicillin allergy who were prescribed empirical carbapenems, median time to carbapenem deescalation was significantly shorter in the postintervention versus preintervention period (2.0 vs 4.2 days, p=0.004). CONCLUSION: Penicillin allergy was a significant contributor to carbapenem use in community-onset gram-negative BSI. This was subject to modification by antimicrobial stewardship interventions, which successfully reduced overall carbapenem use and duration of carbapenem therapy in patients with penicillin allergy.
引用
- Al-Hasan MN, Acker EC, Kohn JE, et al. Impact of Penicillin Allergy on Empirical Carbapenem Use in Gram-Negative Bloodstream Infections: An Antimicrobial Stewardship Opportunity. Pharmacotherapy. 2017. PMID: 29105102. doi:10.1002/phar.2054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。